This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Case for Drug Stocks

You don't need to be a doctor or an economist to know that rising interest rates have been something of a tonic for Big Pharma. And you also don't need to be a mutual fund portfolio manager to know that the rise in drug stocks is making health care fund managers feel better.

The nearly indistinguishable one-month charts plotting the rising yield on the 10-year Treasury note and the Amex Pharmaceutical Index (DRG) shows the tight connection between rising rates and drug stock performance. Both benchmarks bottomed out in late March, with the yield on the 10-year Treasury dropping to 3.67% on March 24, and then rocketing up to its recent range around the 4.40% level. Over the same period, the pharma index rose 4.5% vs. only 3.2% for the S&P 500.

Since diversified health care funds have their heaviest weightings in large-cap drug stocks (on average between 40% to 60%), the rise in Big Pharma also powered health care funds toward the best one-month performance of any category of domestic equity funds, rising 2.37%, according to Morningstar.

"Historically, when the Fed begins to raise rates, the pharma stocks are relative outperformers," says David Moscowitz, analyst at Friedman Billings Ramsey. (To see a contrarian view on this topic published last week, click here .)

Perhaps the best example of the historical link between rates and drug stocks took place in 1994-95 when the Fed aggressively raised overnight lending rates from 3% to 6% in about a year's time. During that period, the pharma index rose over 25% compared to a mere 2% gain for the S&P 500.

Albert Rauch, analyst at AG Edwards, says drug stocks become popular during a rising interest rate environment because they trade independently of the economic cycle. Unlike housing, auto and financial stocks, which can be whipsawed by interest rate moves by the Fed, drug stocks are far less sensitive to rate increases, partly because the industry carries a lighter debt load.

Checking Up on Health Care Funds
(Returns through 4/15/04)
Fund Ticker YTD 3 Years 5 Years Expense Ratio
Eaton Vance Worldwide Health Sciences ETHSX 4.41% 4.06% 18.14% 1.97%
Evergreen Health Care EHCYX 6.25 15.79 - 1.75
Munder Healthcare MFHYX 10.86 4.61 20.09 1.89
Fidelity Select Health Care FSPHX 6.03 - - 0.99
State Street Research Health Sciences SHSSX 8.64 18.48 - 1.25
T. Rowe Price Health Sciences PRHSX 10.03 10.06 11.96 1.00
Vanguard Health Care VGHCX 3.93 7.47 13.03 0.28
Amex Pharmaceutical Index ^DRG -2.4 -13.9 -16.5 -
S&P 500 SPX 1.95 -0.07 -1.76 -
Source: Morningstar

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs